עם ישראל חי
Israel delivery includedPriced BAC Water and NAD+ in ILS · estimated 1–2 business-day delivery (Sunday–Thursday)Choose a product →
Laboratory research materials only · Research purchaser verification required
My account ↗
Israel · ILS checkout for priced BAC Water and NAD+ sizes only · other materials by inquiry

Retatrutide research: RETA, Phase 3 trials and evidence limits

Retatrutide, also known as LY3437943 or informally RETA, is an investigational molecule studied for activity at GIP, GLP-1 and glucagon receptors. “GLP-3” is an informal catalog label, not the name of a third GLP receptor or an approval category.

RETA is a search abbreviation. Retatrutide is the full molecule name; LY3437943 is its development identifier. Keep these names connected on one reference page instead of treating each Hebrew spelling as a different product.

Retatrutide name and identity cross-reference

Retatrutide name and identity cross-reference
Name on a pageWhat it meansWhat it does not verify
Retatrutide / LY3437943The molecule and its development identifierA commercial vial’s identity, quantity or provenance
RETA / רטא / רטטרוטייד / רטטרוטידAbbreviations and Hebrew transliterations used in searchesA separate medicine, batch or quality grade
GLP-3 / L∅C 3RInformal catalog or brand labels in this contextA third GLP receptor or regulatory approval

Common questions

Is RETA the same name as retatrutide?

RETA is commonly used as shorthand for retatrutide, but a short name does not authenticate material. Use the full chemical identity and match the sample and lot to the original laboratory record.

Does a retatrutide clinical trial validate a catalog vial?

No. A trial concerns its defined study product, participants and protocol. A supplier’s vial needs its own identity and lot documentation; a medicine-status question must be checked separately against the exact product record.

The 2026 update: Phase 3 is now published

Retatrutide / LY3437943 is studied as a GIP, GLP-1 and glucagon receptor agonist. The peer-reviewed TRIUMPH-1 report appeared September 29, 2026, after the earlier Phase 2 report. Phase 3 publication is not marketing authorization and does not authenticate a separately supplied vial.

For the actual participant counts, follow-up, weight endpoints and estimand differences, use our maintained clinical-trial comparison linked below. Keeping the full results in one comparison avoids inconsistent duplicated tables. For רטטרוטייד, רטטרוטיד or רטא searches, retain the English name to distinguish the molecule from a shorthand or storefront code.

Retatrutide in Israel: read the official trial record

The Israeli Ministry of Health record MOH_2024-03-07_013284 describes protocol J1I-MC-GZBO, a randomized, double-blind, placebo-controlled Phase 3 study of cardiovascular and kidney outcomes. The sponsor identifies this protocol as TRIUMPH-Outcomes, NCT06383390. It is a separate research question from the weight-change trials summarized in our comparison.

Checked October 22, 2026: the Israeli record displayed recruiting and identified the study product as not registered. These are dated registry fields, not a guarantee of an open place at a particular center or a complete eligibility assessment. A trial record is not a published outcome, marketing authorization or authentication of a supplier vial. Locked Aminos is not represented here as a trial site, sponsor or enrollment service; use the official record for current research information.

Primary sources and verification records

Illustrative laboratory vials forming the Locked Aminos wordmark
Illustration only, not evidence of a tested batch.

Names identify the topic, not the batch

Hebrew searches may use רטטרוטייד, רטטרוטיד, רטאטרוטייד, רטרוטייד, רטא or רטה. Keep these as spelling aids on one reference page. When matching laboratory records, use the complete scientific name, chemical form, sample and lot. The L∅C 3R brand code does not replace that identification.

Read the trial before the headline

The 2023 peer-reviewed phase 2 trial investigated retatrutide in adults with obesity. It reported clinical outcomes for a defined study product, protocol and population. Its results are not a quality certificate for a commercial vial. Subsequent development should be checked against dated primary publications and the developer’s current statements, not an undated supplier summary.

Investigational status is not a purchasing instruction

Lilly’s September 2026 communication describes retatrutide as investigational and available legally only through its clinical trials. This reference does not represent any catalog material as Lilly’s trial product, an approved medicine or a route to clinical participation. The Israeli regulatory status of a specific medicine must be checked with the relevant authority.

How to compare the metabolic compounds

Semaglutide, tirzepatide and retatrutide have different receptor profiles and development histories. Counting receptor targets does not rank safety or prove superior outcomes. Comparisons require the same outcome definition, follow-up and population, preferably a suitable direct trial. None of these comparisons supplies a self-treatment plan.

Sources and review scope

Sources explain terminology and evidence limits. They are not commercial endorsements or approvals of catalog products. Check the original source for updates.

Catalog identity and documentation

These links identify laboratory materials, not treatments or clinical-trial products.